| Name |
CAS |
MF |
MW |
Single-letter sequence |
Three-letter sequence |
Number of AA |
Type |
Inquiry |
| GGVTLTYQFAAGPRDK |
|
C75H117N21O23 |
1680.86 |
H2N-GGVTLTYQFAAGPRDK-OH |
H2N-Gly-Gly-Val-Thr-Leu-Thr-Tyr-Gln-Phe-Ala-Ala-Gly-Pro-Arg-Asp-Lys-OH |
16 |
CD11c-targeting peptide |
|
| mUNO |
|
C22H39N7O8S1 |
561.65 |
H2N-CSPGAK-OH |
H2N-Cys-Ser-Pro-Gly-Ala-Lys-OH |
6 |
M2 macrophage–targeting peptide |
|
| TMGFTAPRFPHY |
|
C67H93N17O16S1 |
1424.62 |
H2N-TMGFTAPRFPHY-OH |
H2N-Thr-Met-Gly-Phe-Thr-Ala-Pro-Arg-Phe-Pro-His-Tyr-OH |
12 |
Tumor neovascular endothelial cell–targeting peptide |
|
| PLSWT7 |
|
C38H67N15O13S3 |
1038.23 |
H2N–CSDRIMRGC–OH |
H2N–Cys–Ser–Asp–Arg–Ile–Met–Arg–Gly–Cys–OH |
9 |
Bladder cancer cell–targeting peptide |
|
| UNO |
|
C36H65N13O11S2 |
920.11 |
H2N-CSPGAKVRC-OH |
H2N-Cys-Ser-Pro-Gly-Ala-Lys-Val-Arg-Cys-OH |
9 |
M2 macrophage–targeting peptide |
|
| PL1 |
|
C61H112N20O15 |
1365.67 |
H2N-PPRRGLIKLKTS-OH |
H2N-Pro-Pro-Arg-Arg-Gly-Leu-Ile-Lys-Leu-Lys-Thr-Ser-OH |
12 |
Prostate cancer–targeting peptide |
|
| Lin TT1 |
|
C36H68N16O12 |
917.03 |
H2N-AKRGARSTA-OH |
H2N-Ala-Lys-Arg-Gly-Ala-Arg-Ser-Thr-Ala-OH |
9 |
p32-targeting peptid |
|
| GCPRPRGDNPPLTCKQDSDCLAGCVCGPNGFCG |
|
C134H213N43O45S6 |
3338.78 |
H2N-GCPRPRGDNPPLTCKQDSDCLAGCVCGPNGFCG-OH |
H2N-Gly-Cys-Pro-Arg-Pro-Arg-Gly-Asp-Asn-Pro-Pro-Leu-Thr-Cys-Lys-Gln-Asp-Ser-Asp-Cys-Leu-Ala-Gly-Cys-Val-Cys-Gly-Pro-Asn-Gly-Phe-Cys-Gly-OH |
33 |
α/β integrin–targeting peptide |
|
| PL3 |
|
C36H69N17O9 |
884.04 |
H2N-AGRGRLVR-OH |
H2N-Ala-Gly-Arg-Gly-Arg-Leu-Val-Arg-OH |
8 |
Tenascin-C–targeting peptide |
|
| GE11 |
|
C75H97N17O19 |
1540.68 |
H2N-YHWYGYTPQNVI-OH |
H2N-Tyr-His-Trp-Tyr-Gly-Tyr-Thr-Pro-Gln-Asn-Val-Ile-OH |
12 |
EGFR-targeting peptide |
|
| A6 |
|
C37H59N9O15 |
869.92 |
H2N-KPSSPPEE-OH |
H2N-Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu-OH |
8 |
CD44-targeting peptide |
|
| P7 |
|
C37H63N7O9 |
749.94 |
H2N-LPLTPLP-OH |
H2N-Leu-Pro-Leu-Thr-Pro-Leu-Pro-OH |
7 |
Hsp90-targeting peptide |
|
| PPL-C |
|
C68H103N17O16 |
1414.65 |
H2N-VSVSHFQKVWVV-OH |
H2N-Val-Ser-Val-Ser-His-Phe-Gln-Lys-Val-Trp-Val-Val-OH |
12 |
PD-L1–targeting peptide |
|
| CREKA peptide |
|
C23H43N9O8S1 |
605.71 |
H2N-CREKA-OH |
H2N-Cys-Arg-Glu-Lys-Ala-OH |
5 |
Fibrin-targeting peptide |
|
| ET |
|
C62H102N18O19S1 |
1435.65 |
H2N–ESYSAKHRIMLT–OH |
H2N–Glu–Ser–Tyr–Ser–Ala–Lys–His–Arg–Ile–Met–Leu–Thr–OH |
12 |
LRG1-targeting peptide |
|
| T7 |
|
C38H58N12O9S1 |
859.01 |
H2N-CHAIYPR-OH |
H2N-Cys-His-Ala-Ile-Tyr-Pro-Arg-OH |
7 |
Glioblastoma cell-targeting peptides |
|
| P51 |
|
C106H134N24O28S1 |
2224.41 |
H2N-CDTFPYLGWWNPNEYRY-OH |
H2N-Cys-Asp-Thr-Phe-Pro-Tyr-Leu-Gly-Trp-Trp-Asn-Pro-Asn-Glu-Tyr-Arg-Tyr-OH |
17 |
HER2-positive cell–targeting peptide |
|
| L5 |
|
C72H116N22O21 |
1625.83 |
H2N-RLNVGGTYFLTTRQ-OH |
H2N-Arg-Leu-Asn-Val-Gly-Gly-Thr-Tyr-Phe-Leu-Thr-Thr-Arg-Gln-OH |
14 |
GPC-3–targeting peptide |
|
| L5-2 |
|
C43H65N11O12 |
928.04 |
H2N-YFLTTRQ-OH |
H2N-Tyr-Phe-Leu-Thr-Thr-Arg-Gln-OH |
7 |
GPC-3–targeting peptide |
|
| PDLong1 |
|
C111H162N24O27S1 |
2296.68 |
H2N-FMTYWHLLNAFTVTVPKDL-OH |
H2N-Phe-Met-Thr-Tyr-Trp-His-Leu-Leu-Asn-Ala-Phe-Thr-Val-Thr-Val-Pro-Lys-Asp-Leu-OH |
19 |
PD-L1–targeting peptide |
|
